Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ELAVL1
REST API REST API
Homo sapiens
ELAVL1 is differentially expressed in 326 experiments: 170 organism parts: brain, liver, ... (168 more);, 261 disease states: normal, control, ... (259 more);, 106 cell types 442 cell lines 42 compound treatments and 87 other conditions.
Synonyms MelG, HUR, Hua
Orthologs elavl1 (Danio rerio)   ELAVL1 (Gallus gallus)   hug (Danio rerio)   Elavl1 (Mus musculus)   Q3ZCE2_BOVIN (Bos taurus)   Elavl1 (Rattus norvegicus)   fne (Drosophila melanogaster)   Rbp9 (Drosophila melanogaster)   elav (Drosophila melanogaster)   ENSXETG00000008752 (Xenopus laevis)   (Compare orthologs)
Gene Ontology Term cytosol, protein binding, cytoplasm, nucleic acid binding, RNA metabolic process, mRNA 3'-UTR binding, mRNA binding, multicellular organismal development, nucleus, nucleotide binding, nucleoplasm, RNA binding, mRNA stabilization, mRNA metabolic process, 3'-UTR-mediated mRNA stabilization
InterPro Term Hud_Sxl_RNA, ELAD_HUD_SF, RRM_dom
UniProt Accession Q15717, B4DVB8
Search EB-eye ENSG00000066044
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-GEOD-3526, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (39 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
Jurkat
3
E-GEOD-1880, E-MEXP-2197, E-MTAB-62
MCF-7
3
E-GEOD-3529, E-GEOD-20081, E-GEOD-19639
LNCaP
2
E-GEOD-14990, E-GEOD-14464
MDA468
2
E-MTAB-62, E-MEXP-440
A549
2
E-GEOD-3202, E-GEOD-6013
436 more value(s).


Cell type

studied in E-MEXP-1121, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (50 experiments)

Factor Value U/D Experiments
CD4+ T cell
2
E-GEOD-16190, E-AFMX-5
fibroblast
1
2
E-GEOD-26672, E-GEOD-3920, E-GEOD-3204
CD56+ NK cells
1
E-AFMX-5
osteoblast
1
E-MEXP-1216
ovarian cancer
1
E-GEOD-21154
monolayer recovery
1
E-GEOD-4219
100 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-GEOD-12254, E-MEXP-2280, ... (77 experiments)

Factor Value U/D Experiments
colon carcinoma
3
E-MTAB-62, E-MTAB-37, E-GEOD-3726
lung adenocarcinoma
3
E-MTAB-37, E-MEXP-231, E-MTAB-62
prostate carcinoma
3
E-MEXP-2034, E-MTAB-62, E-MEXP-1327
astrocytoma
2
E-GEOD-4290, E-MTAB-37
dermatomyositis
2
E-MTAB-62, E-GEOD-5370
acute lymphoblastic leukemia
2
E-MTAB-37, E-MTAB-62
255 more value(s).


Compound treatment

studied in E-GEOD-5258, E-TABM-782, E-GEOD-5824, E-TABM-868, E-MEXP-1958, ... (32 experiments)

Factor Value U/D Experiments
none
4
6
E-GEOD-20719, E-GEOD-5824, E-TABM-782, E-MEXP-1601, E-GEOD-412, ... (10 experiments)
glutamine
2
E-MEXP-1335, E-MEXP-941
2-(3,4,5-trimethoxy-phenylamino)-pyrrolo[2,3-d]pyrimidines
1
1
E-GEOD-6932
5-aza-2'-deoxycytidine + trichostatin A
1
E-MEXP-1269
bis [(+)-tartrato] diantimonate (III) dipotassium trihydrate
1
E-GEOD-6907
bacterial endotoxin
1
E-GEOD-3284
36 more value(s).


Age at diagnosis

studied in E-GEOD-21653, E-GEOD-4922

Factor Value U/D Experiments
35
1
1
E-GEOD-21653
52 years
1
1
E-GEOD-4922


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-17189, E-GEOD-6710, E-GEOD-19348, ... (11 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-6236, E-GEOD-4667, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-GEOD-21887 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (7 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-3494, E-GEOD-17476, E-GEOD-21750, E-GEOD-22593, ... (11 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-7011, E-MEXP-2657, E-GEOD-20540, E-GEOD-22278, E-GEOD-20505, ... (16 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-3720, E-MEXP-2069, E-TABM-26, ... (33 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-MEXP-561

Injury
studied in E-GEOD-19743

Irradiate
studied in E-TABM-321, E-MEXP-2177

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-19703, E-GEOD-1493, E-GEOD-21750, E-GEOD-1657, ... (6 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

Replicate
studied in E-GEOD-10896, E-GEOD-17204

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643, E-GEOD-7307

Sirna
studied in E-GEOD-21575, E-GEOD-21574

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

tissue (organ)
studied in E-GEOD-22601

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-22152, E-MEXP-973, E-GEOD-19246, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-GEOD-6532, E-GEOD-4922

Tumor size
studied in E-GEOD-6532

Vehicle
studied in E-GEOD-5258

Processing time: 0.261 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM